These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33409724)

  • 1. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients.
    Chow R; Chiu L; Herrstedt J; Aapro M; Lock M; DeAngelis C; Navari RM
    Support Care Cancer; 2021 Aug; 29(8):4269-4275. PubMed ID: 33409724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.
    Chanthawong S; Lim YH; Subongkot S; Chan A; Andalusia R; Ahmad Bustamam RS; Chaiyakunapruk N
    Support Care Cancer; 2019 Mar; 27(3):1109-1119. PubMed ID: 30112718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis.
    Yokoe T; Hayashida T; Nagayama A; Nakashoji A; Maeda H; Seki T; Takahashi M; Takano T; Abe T; Kitagawa Y
    Oncologist; 2019 Jun; 24(6):e347-e357. PubMed ID: 30333194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis.
    Botteman M; Nickel K; Corman S; Turini M; Binder G
    Support Care Cancer; 2020 Feb; 28(2):857-866. PubMed ID: 31161436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis.
    Zhang Z; Zhang Y; Chen G; Hong S; Yang Y; Fang W; Luo F; Chen X; Ma Y; Zhao Y; Zhan J; Xue C; Hou X; Zhou T; Ma S; Gao F; Huang Y; Chen L; Zhou N; Zhao H; Zhang L
    Oncologist; 2018 May; 23(5):603-616. PubMed ID: 29330211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan.
    Osman AAM; Elhassan MMA; AbdElrahim BHA; Ahmed FHA; Yousif JBH; Ahmed MAM; Abdelhafeez RHA; Ahmed UMY
    J Glob Oncol; 2018 Sep; 4():1-9. PubMed ID: 30241275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
    Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
    Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.
    Bosnjak SM; Dimitrijevic J; Djordjevic F
    Curr Opin Support Palliat Care; 2016 Jun; 10(2):180-8. PubMed ID: 27028050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature.
    Chow R; Herrstedt J; Aapro M; Chiu L; Lam H; Prsic E; Lock M; DeAngelis C; Navari RM
    Support Care Cancer; 2021 Jul; 29(7):3439-3459. PubMed ID: 33442782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review.
    Hocking CM; Kichenadasse G
    Support Care Cancer; 2014 Apr; 22(4):1143-51. PubMed ID: 24522741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of palonosetron and dexamethasone-based triple and quadruple regimens in preventing highly emetogenic chemotherapy-induced nausea and vomiting.
    Halloush S; Alhifany AA; Alkhatib NS; Al Bawab AQ; Al-Qawasmeh B; Al Shawakri E; Koeller J
    Curr Med Res Opin; 2022 Apr; 38(4):571-577. PubMed ID: 35068277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis.
    Filetti M; Lombardi P; Giusti R; Falcone R; Scotte F; Giannarelli D; Carcagnì A; Altamura V; Scambia G; Daniele G
    Cancer Treat Rev; 2023 Apr; 115():102512. PubMed ID: 36774658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
    Clemmons AB; Orr J; Andrick B; Gandhi A; Sportes C; DeRemer D
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2065-2071. PubMed ID: 29906570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials.
    Zhou JG; Huang L; Jin SH; Xu C; Frey B; Ma H; Gaipl US
    ESMO Open; 2020 Feb; 5(1):. PubMed ID: 32079622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting.
    Burke TA; Wisniewski T; Ernst FR
    Support Care Cancer; 2011 Jan; 19(1):131-40. PubMed ID: 20101417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Vimolchalao V; Sakdejayont S; Wongchanapai P; Sukprakun S; Angspatt P; Thawinwisan W; Chenaksara P; Sriuranpong V; Vinayanuwatikun C; Parinyanitikun N; Poovorawan N; Tanasanvimon S
    Int J Clin Oncol; 2020 Feb; 25(2):396-402. PubMed ID: 31776732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin.
    Navari RM; Ruddy KJ; LeBlanc TW; Nipp R; Clark-Snow R; Schwartzberg L; Binder G; Bailey WL; Potluri R; Schmerold LM; Papademetriou E; Roeland EJ
    Oncologist; 2021 Apr; 26(4):325-331. PubMed ID: 33289268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexamethasone-Free Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy: A Double-Blind, Phase III Randomized Controlled Trial (CINV POD study).
    Radhakrishnan V; Venkatakrishnan K; Perumal Kalaiyarasi J; Selvarajan G; Mahaboobasha N; Victor PV; Anbazhagan M; Sivanandam DM; Rajaraman S
    JCO Glob Oncol; 2024 Jan; 10():e2300301. PubMed ID: 38237092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting.
    Park SH; Binder G; Corman S; Botteman M
    J Med Econ; 2019 Aug; 22(8):840-847. PubMed ID: 31094589
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.